Induction of cytotoxicity and ssDNA breaks by 9-bromo-5-morpholino-tetrazolo[1,5-c]quinazoline in tumor cells cultured in vitro

Toxicology in Vitro

Volumn 17, Issue 4, 2003, Pages 457-463

  Jantova S ^a   Cipak L' ^b   Slamenova D ^b   Horvath V ^a   Rauko, P ^b  

^a SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Apoptosis; Cytotoxicity; DNA single strand breaks; Quinazolines

Indexed keywords

9 BROMO 5 MORPHOLINOTETRAZOLO[1,5 C]QUINAZOLINE; DNA FRAGMENT; QUINAZOLINE DERIVATIVE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL STRAIN CACO 2; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LEUKEMIA CELL LINE;

MURINAE;

EID: 0038771104     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-2333(03)00066-3     Document Type: Article

References (39)

1. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., LoRusso P., Rischin D., Sauleda S., Gee J., Nicholson R.I., Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients. histopathologic and molecular consequences of receptor inhibition Journal of Clinical Oncology. 1:2002;110-124.
2. Ahnstrom G., Erixon K. Measurement of strand breaks by alkaline denaturation and hydroxylapatite chromatography. Friedberg E.C., Hanawalt P.C. DNA Repair. A Laboratory Manual of Research Procedures. 1981;403-418 New York, Marcel Dekker.
3. Bekhit A.A., Habib N.S., el-Din A., Bekhit A. Synthesis and antimicrobial evaluation of chalcone and syndrome derivatives of 4(3H)-quinazolinone. Bollettino Chimico Farmaceutico. 140:2001;297-301.
4. Benning C.M., Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostrate cancer cell apoptosis via an alpha1-adenoceptor-independent action. Cancer Res. 2:1992;597-602.
5. Baselga J., Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs. 60:2000;33-42.
6. Callais F., Min S., Giorgi-Renault S., Festy B. Structure-activity relationships of a series of antitumoral 5,8-quinazolinediones in mutagenicity studies. Mutation Research. 261:1991;51-56.
7. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., Bianco A.R., Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clinical Cancer Research. 6:2000;2053-2063.
8. Chao Q., Deng L., Shih H., Leoni L.M., Genini D., Carson D.A., Cottam H.B. Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha. Journal of Medicinal Chemistry. 42:1999;3860-3873.
9. Collins A.R., Ai-guo M., Duthir S.J. The kinetics of repair of oxidative DNA damage (strand breaks and oxidized pyrimidine dimmers) in human cells. Mutation Research. 336:1995;69-77.
10. Eisa H.M. Fused pyrimidines. Synthesis of new derivatives of potential diuretic activity. Bollettino Chimico Farmaceutico. 135:1996;585-590.
11. Faust R.A., Tawfic S., Davis A.T., Ahmed K. Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor. Oral Oncology. 35:1999;290-295.
12. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., Ono M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Research. 62:2002;2554-2560.
13. Ishihara T., Kohno K., Ushio S., Iwaki K., Ikeda M., Kurimoto M. Tryptanthrin inhibits nitric oxide and prostaglandin E(2) synthesis by murine macrophages. European Journal of Pharmacology. 407:2000;197-204.
14. Jackman A.L., Taylor G.A., Girson W., Kimbeli R., Brown M., Calvert A.H., Judson I.R., Hughes L.R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Research. 51:1991;5579-5586.
15. Jantová S., Ružeková L'., Špirková K., Stankovský Š. Cytotoxic effect of substituted tetrazolo[1,5-c]quinazolines on HeLa cells. Biology. 52:1997;445-450.
16. Jantová S., Ružeková L'., Stankovský Š., Špirková K. Antiproliferation activity and the mechanism of action of 9-bromo-5-morpholino-tetrazolo[1,5-c]quinazoline - potentional anticancer drug. Neoplasma. 44:1997;240-246.
17. Karnes W.E. Jr., Weller S.G., Adjei P.N., Kottke T.J., Glenn K.S., Gores G.J., Kaufmann S.H. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology. 114:1998;930-939.
18. Kaye S.B. New antimetabolites in cancer chemotherapy and their clinical impact. British Journal of Cancer. 78:1998;1-7.
19. Kimoto T., Hino K., Koya-Miyata S., Yamamoto Y., Takeuchi M., Nishizaki Y., Micallef M.J., Ushio S., Iwaki K., Ikeda M., Kurimoto M. Cell differentiation and apoptosis of monocytic and promyelocytic leukemia cells (U-937 and HL-60) by tryptanthrin, an active ingredient of Polygonum tinctorium Lour. Pathology International. 51:2001;315-325.
20. Labuda J., Buèková M., Jantová S., Štepánek I., Surugiu I., Danielsson B., Mascini M. Modified screen-printed electrodes for the investigation of the interaction of non-electroactive quinazoline derivatives with DNA. Fresenius Journal of Analytic Chemistry. 367:2000;364-368.
21. Lasztoczi B., Kovacs R., Nyikos L., Kardos J. A glutamate receptor subtype antagonist inhibits seizures in rat hippocampal slices. Neuroreport. 13:2002;351-356.
22. Lopez-Farre A., Rodriguez-Feo J.A., Garcia-Colis E., Gomez J., Lopez-Blaya A., Fortes J., de Andres R., Rico L., Casado S. Reduction of the soluble cyclic GMP vasorelaxing system in the vascular wall of stroke-prone spontaneously hypertensive rats. effect of the alpha1-receptor blocker doxazosin Journal of Hypertension. 20:2002;463-470.
23. Maggio B., Daidone G., Raffa D., Plescis S., Mantione L., Catena Cutuli V.M., Mangano N.G., Caruso A. Synthesis and pharmacological study of ethyl 1-methyl-5-(substituted 3,4-dihydro-4-oxoquinazolin-3-yl)-1H-pyrazole-4-acetates. European Journal of Medicinal Chemistry. 36:2001;737-742.
24. Marsham P.R. Quinazoline inhibitors of thymidylate synthase - potent new anticancer agents. Journal of Heterocyclic Chemistry. 31:1994;603-613.
25. Matsui S.I., Arredondo M.A., Wrzosek C., Rustum Y.M. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Research. 56:1996;4715-4723.
26. Mayer-Kuckuk P., Banerjee D., Malhotra S., Doubrovin M., Iwamoto M., Akhurst T., Balatoni J., Bornmann W., Finn R., Larson S., Fong Y., Gelovani Tjuvajev J., Blasberg R., Bertino J.R. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase. a method to modulate gene expression Proccedings of the National Academy of Sciences of the U.S.A. 99:2002;3400-3405.
27. Narla R.K., Liu X.P., Myers D.E., Uckun F.M. 4-(3α-Bromo-4′hydroxylphenyl)-amino-6,7-dimethoxyquinazoline. a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells Clinical Cancer Research. 4:1998;1405-1414.
28. Panadero A., Yin M.B., Voigt W., Rustum Y.M. Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331. Oncology Research. 7:1995;73-81.
29. Pandeya S.N., Sriram D., Nath G., De Clercq E. Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one. Pharmaceutica Acta Helvetiae. 74:1999;11-17.
30. Singh S.K., Paliwal J.K., Grover P.K., Gupta R.C. Quantification of 2,3-dihydro-7-methoxypyrrolo-[2,1-b]-quinazolin-9(1H)-one, a new antiallergic agent, by high-performance liquid chromatography in serum. Journal of Chromatography B: Biomedical Sciences and Applications. 658:1994;198-201.
31. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantification of low levels of DNA damage in individual cells. Exp. Cell Res. 175:1988;184-191.
32. Scheithauer W., Kornek G.V., Ulrich-Pur H., Penz M., Raderer M., Salek T., Haider K., Kwasny W., Depisch D. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma. results of a phase I-II trial Cancer. 91:2001;1264-1271.
33. Srivastava V.K., Palit G., Agarwal A.K., Shanker K. Antiparkinsonian activity and behavioural effects of newer quinazolinones. Pharmacological Research Communications. 19:1987;617-628.
34. Stankovský Š., Špirková K. Amidinoyl isothiocyanates in the synthesis of condensed heterocycles: tetrazolo-azidoazodomethine tautomerism in substituted tetrazolo[1,5-c] quinazolines. Monatschefte für Chemie. 122:1991;849-852.
35. Stevens G.J., LaVoie E.J., McQueen C.A. The role of acetylation in the mutagenicity of the antitumor agent, batracylin. Carcinogenesi. 17:1996;115-119.
36. Stoll S.W., Benedict M., Mitra R., Hiniker A., Elder J.T., Nunez G. EGF receptor signaling inhibits keratinocyte apoptosis. evidence for mediation by Bcl-XL Oncogene. 16:1998;1493-1499.
37. Tamura T. Molecular target-based cancer therapy. epidermal growth factor receptor inhibitors Nippon Geka Gakkai Zasshi. 103:2002;233-236.
38. Takimo C.H. Antifolates in clinical development. Seminars in Oncology. 24:1997;18-51.
39. Yin M.B., Voigt W., Panadero A., Vanhoefer U., Frank C., Pajovic S., Azizkhan J., Rustum Y.M. p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). Molecular Pharmacology. 51:1997;630-636.